- Home
- EYPT vs LADR Comparison
EYPT vs LADR Comparison
Compare EYPT & LADR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | LADR |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate Investment Trusts |
| Sector | Industrials | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2005 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EYPT | LADR |
|---|---|---|
| Price | $13.97 | $9.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $31.80 | $12.25 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 8.98% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | $31.66 |
| Revenue Next Year | $3,115.57 | $16.92 |
| P/E Ratio | ★ N/A | $500.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.41 | $9.61 |
| 52 Week High | $19.11 | $11.92 |
Technical Indicators
Market Signals| Indicator | EYPT | LADR |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 44.78 |
| Support Level | $12.01 | $9.94 |
| Resistance Level | $14.52 | $10.44 |
| Average True Range (ATR) | 1.05 | 0.17 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 51.38 | 20.83 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About LADR Ladder Capital Corp
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.